Suchergebnisse - (Person:"Vanden Eynde, Jean Jacques")

PubPharm (43)

1

Repositioning Oxybutynin Hydrochloride: State of the Art in Synthesis, Mode of Action, Metabolism, and Formulations

enthalten in: Preprints.org | 2023

von Vanden Eynde, J.

2

COVID-19 : Failure of the DisCoVeRy Clinical Trial, and Now-New Hopes?

enthalten in: Pharmaceuticals (Basel, Switzerland) | 2021

von Vanden Eynde, J.

3

Dual-Target Inhibitors of the Folate Pathway Inhibit Intrinsically Trimethoprim-Resistant DfrB Dihydrofolate Reductases

enthalten in: ACS medicinal chemistry letters | 2020

von Toulouse, J. | Shi, G. | Lemay-St-Denis, C. | +10

4

COVID-19 : An Update About the Discovery Clinical Trial

enthalten in: Pharmaceuticals (Basel, Switzerland) | 2020

von Vanden Eynde, J.

5

COVID-19 : A Brief Overview of the Discovery Clinical Trial

enthalten in: Pharmaceuticals (Basel, Switzerland) | 2020

von Vanden Eynde, J.

6

2019 : An Awesome Year for Pharmaceuticals

enthalten in: Pharmaceuticals (Basel, Switzerland) | 2020

von Vanden Eynde, J.

7

Breakthroughs in Medicinal Chemistry : New Targets and Mechanisms, New Drugs, New Hopes-6

enthalten in: Molecules (Basel, Switzerland) | 2019

von Vanden Eynde, J. | Mangoni, A. | Rautio, J. | +39

8

Bioactive Aliphatic Polycarbonates Carrying Guanidinium Functions : An Innovative Approach for Myotonic Dystrophy Type 1 Therapy

enthalten in: ACS omega | 2019

von Baroni, A. | Neaga, I. | Delbosc, N. | +9

9

Tafenoquine : A 2018 Novel FDA-Approved Prodrug for the Radical Cure of Plasmodium vivax Malaria and Prophylaxis of Malaria

enthalten in: Pharmaceuticals (Basel, Switzerland) | 2019

von Mayence, A. | Vanden Eynde, J.

10

Structure-Based Design of Dimeric Bisbenzimidazole Inhibitors to an Emergent Trimethoprim-Resistant Type II Dihydrofolate Reductase Guides the Design of Monomeric Analogues

enthalten in: ACS omega | 2019

von Toulouse, J. | Yachnin, B. | Ruediger, E. | +11

1
2
3
4
5
Nächster »
[5]